Abstract | BACKGROUND: METHODS: The effect of a single oral dose of cilostazol on BHR was studied in 10 elderly patients with clinically stable asthma, with a mean age of 59.5+/-4.8 years, in a double-blind, crossover, placebo-controlled study. Each subject received 100 mg of cilostazol, 200 mg of theophylline as a positive control or a placebo in a random order. The subjects underwent a methacholine challenge test 3 h after each drug administration on three occasions separated by 2 weeks. RESULTS: The geometric mean value of the provocative concentration of methacholine causing a 20% fall in forced expiratory volume in 1 s (PC20-FEV1) with cilostazol was 0.48 mg/ml [geometric standard error of the mean (GSEM), 1.40] which was significantly (p<0.01) greater than that with the placebo [0.25 mg/ml (GSEM, 1.36)]. The value with theophylline [0.32 mg/ml (GSEM, 1.54)] did not differ significantly from that with cilostazol or the placebo. Baseline forced vital capacity (FVC) and FEV1 values significantly (p<0.05 and p<0.001, respectively) increased with cilostazol from 2.73+/-0.25 and 1.52+/-0.17 to 2.86+/-0.23 and 1.65+/-0.17 liters, respectively. Theophylline did not significantly increase the FVC or FEV1 value. CONCLUSION:
|
Authors | M Fujimura, Y Kamio, S Myou, T Hashimoto, T Matsuda |
Journal | International archives of allergy and immunology
(Int Arch Allergy Immunol)
Vol. 114
Issue 4
Pg. 379-84
(Dec 1997)
ISSN: 1018-2438 [Print] Switzerland |
PMID | 9414143
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Phosphodiesterase Inhibitors
- Tetrazoles
- Theophylline
- 3',5'-Cyclic-AMP Phosphodiesterases
- Cyclic Nucleotide Phosphodiesterases, Type 3
- Cilostazol
|
Topics |
- 3',5'-Cyclic-AMP Phosphodiesterases
(antagonists & inhibitors)
- Administration, Oral
- Aged
- Asthma
(drug therapy, physiopathology)
- Bronchial Hyperreactivity
(drug therapy)
- Cilostazol
- Cyclic Nucleotide Phosphodiesterases, Type 3
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Phosphodiesterase Inhibitors
(administration & dosage, therapeutic use)
- Respiratory Function Tests
- Tetrazoles
(administration & dosage, therapeutic use)
- Theophylline
(therapeutic use)
|